JP2005505527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505527A5 JP2005505527A5 JP2003518618A JP2003518618A JP2005505527A5 JP 2005505527 A5 JP2005505527 A5 JP 2005505527A5 JP 2003518618 A JP2003518618 A JP 2003518618A JP 2003518618 A JP2003518618 A JP 2003518618A JP 2005505527 A5 JP2005505527 A5 JP 2005505527A5
- Authority
- JP
- Japan
- Prior art keywords
- contrast agent
- groups
- iodinated contrast
- branched
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002872 contrast media Substances 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 230000005415 magnetization Effects 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical group 0.000 claims 3
- 150000001720 carbohydrates Chemical group 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000011835 investigation Methods 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 238000012307 MRI technique Methods 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000002583 angiography Methods 0.000 claims 2
- 150000001491 aromatic compounds Chemical class 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000013155 cardiography Methods 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229960004108 iobitridol Drugs 0.000 claims 1
- YLPBXIKWXNRACS-UHFFFAOYSA-N iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 claims 1
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 claims 1
- 229960004901 iodamide Drugs 0.000 claims 1
- 230000026045 iodination Effects 0.000 claims 1
- 238000006192 iodination reaction Methods 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- -1 ioflatol Chemical compound 0.000 claims 1
- 229960004647 iopamidol Drugs 0.000 claims 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims 1
- 229960002603 iopromide Drugs 0.000 claims 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229960000554 metrizamide Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000009608 myelography Methods 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000007487 urography Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI001706A ITMI20011706A1 (it) | 2001-08-03 | 2001-08-03 | Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic |
| PCT/EP2002/008183 WO2003013616A1 (en) | 2001-08-03 | 2002-07-23 | Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005505527A JP2005505527A (ja) | 2005-02-24 |
| JP2005505527A5 true JP2005505527A5 (enExample) | 2006-01-12 |
| JP4310187B2 JP4310187B2 (ja) | 2009-08-05 |
Family
ID=11448229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518618A Expired - Fee Related JP4310187B2 (ja) | 2001-08-03 | 2002-07-23 | Ｘ線と核磁気共鳴との組み合わせ診断法で使用するためのイオン性及び非イオン性ｘ線写真造影剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8211404B2 (enExample) |
| EP (1) | EP1411992B1 (enExample) |
| JP (1) | JP4310187B2 (enExample) |
| AT (1) | ATE347912T1 (enExample) |
| DE (1) | DE60216770T2 (enExample) |
| DK (1) | DK1411992T3 (enExample) |
| ES (1) | ES2278946T3 (enExample) |
| IT (1) | ITMI20011706A1 (enExample) |
| WO (1) | WO2003013616A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528424A (ja) | 2004-03-11 | 2007-10-11 | マリンクロッド・インコーポレイテッド | ヨウ化単量体および二量体の混合物を含むｘ線造影剤製剤 |
| DE102005028882A1 (de) * | 2005-06-22 | 2007-01-04 | Siemens Ag | Lösung und Verfahren zum Unterstützen der Bildgebung an einem Patienten |
| US7683617B2 (en) * | 2005-07-21 | 2010-03-23 | Johns Hopkins University | Non-invasive MRI measurement of tissue glycogen |
| EP2073723A4 (en) * | 2006-10-10 | 2011-03-30 | Mayo Foundation | REDUCTION OF CONTRAST-INDICATED TOXICITY |
| JP2011500531A (ja) * | 2007-10-12 | 2011-01-06 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 造影剤 |
| US8323619B2 (en) * | 2007-11-07 | 2012-12-04 | Ge Healthcare As | Contrast agents |
| DE102007058220A1 (de) | 2007-12-03 | 2009-06-04 | Bayer Schering Pharma Aktiengesellschaft | Dimere macrocyclisch substituierte Benzolderivate |
| EP2231200A1 (en) * | 2007-12-05 | 2010-09-29 | GE Healthcare AS | Contrast agents |
| US8535642B2 (en) * | 2008-02-27 | 2013-09-17 | Ge Healthcare As | Contrast agents |
| EP2243767A1 (en) | 2009-04-21 | 2010-10-27 | Bracco Imaging S.p.A | Process for the iodination of aromatic compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2541272A1 (fr) * | 1983-02-23 | 1984-08-24 | Guerbet Sa | Composes bromes et produits opacifiants en contenant |
| AU4546996A (en) | 1995-02-24 | 1996-09-11 | Bracco Research S.A. | Liposome suspensions as blood pool imaging contrast agents |
| US5648536A (en) * | 1995-06-07 | 1997-07-15 | Dunn; Thomas Jeffrey | Process for producing ioversol |
| CA2327816A1 (en) | 1998-04-09 | 1999-10-21 | Nycomed Imaging As | Use of particulate contrast agents in diagnostic imaging for studying physiological parameters |
| EP2025350A3 (en) * | 1999-04-21 | 2009-12-09 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Determining pH by CEDST MRI |
| FR2794744B1 (fr) * | 1999-06-09 | 2001-09-21 | Guerbet Sa | Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale |
-
2001
- 2001-08-03 IT IT2001MI001706A patent/ITMI20011706A1/it unknown
-
2002
- 2002-07-23 JP JP2003518618A patent/JP4310187B2/ja not_active Expired - Fee Related
- 2002-07-23 WO PCT/EP2002/008183 patent/WO2003013616A1/en not_active Ceased
- 2002-07-23 DK DK02758379T patent/DK1411992T3/da active
- 2002-07-23 DE DE60216770T patent/DE60216770T2/de not_active Expired - Lifetime
- 2002-07-23 AT AT02758379T patent/ATE347912T1/de active
- 2002-07-23 US US10/485,878 patent/US8211404B2/en not_active Expired - Fee Related
- 2002-07-23 EP EP02758379A patent/EP1411992B1/en not_active Expired - Lifetime
- 2002-07-23 ES ES02758379T patent/ES2278946T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5324503A (en) | Iodo-phenylated chelates for x-ray contrast | |
| US6660248B2 (en) | Fullerene (C60)-based X-ray contrast agent for diagnostic imaging | |
| JP2854905B2 (ja) | キレート組成物 | |
| JP2005505527A5 (enExample) | ||
| RU2006141979A (ru) | Контрастные агенты для получения изображения кровоснабжения миокарда | |
| Zamora et al. | Historical perspective of imaging contrast agents | |
| JPH09507668A (ja) | イメージング用官能化大環状配位子類 | |
| CN102366632A (zh) | 顺磁性金属配合物功能化的荧光金纳米簇磁共振和荧光成像造影剂 | |
| Bonlawar et al. | Targeted Nanotheranostics: integration of preclinical MRI and Ct in the molecular imaging and therapy of advanced diseases | |
| US20090317327A1 (en) | Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy | |
| ATE365170T1 (de) | Komplexverbindungen aus paramagnetischem metall und phthalocyanin und kontrastmittel, bei dem diese verbindungen verwendet werden | |
| ES2396567T3 (es) | Agentes de contraste | |
| JP4310187B2 (ja) | Ｘ線と核磁気共鳴との組み合わせ診断法で使用するためのイオン性及び非イオン性ｘ線写真造影剤 | |
| Abe et al. | A gemistocytic astrocytoma demonstrated high intensity on MR images: protein hydration layer | |
| ES2259299T3 (es) | Uso de agentes de contraste en la fabricacion de agentes de diagnostico para la visualizacion del lumen intestinal. | |
| Sovak | Introduction: state of the art and design principles of contrast media | |
| NO964501D0 (no) | Liposomsuspensjoner som blod-pool bildekontrastmidler | |
| US7485753B2 (en) | Contrast agents | |
| Kiryu et al. | Interstitial MR lymphography in mice: comparative study with gadofluorine 8, gadofluorine M, and gadofluorine P | |
| Lonnemark | Superparamagnetic particles as an oral contrast medium in abdominal magnetic resonance imaging. | |
| Petiet et al. | Improvement of microscopic MR imaging of amyloid plaques with targeting and non-targeting contrast agents | |
| d'Anjou | Principles of Computed Tomography and | |
| GB2465663A (en) | X-ray contrast agent compositions comprising an iodinated X-ray contrast agent and ethylenediamine-N,N-disuccinic acid | |
| JP6182019B2 (ja) | 高分子化造影剤 | |
| KR101480393B1 (ko) | 간암 진단을 위한 조영제용 가돌리늄 착물과 이를 이용한 간암 진단용 조영제 |